Shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) saw unusually-strong trading volume on Monday . Approximately 6,503,797 shares traded hands during mid-day trading, an increase of 382% from the previous session’s volume of 1,349,783 shares.The stock last traded at $2.33 and had previously closed at $2.00.

Several research analysts have recently issued reports on MRNS shares. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, May 3rd. Jefferies Group reissued a “buy” rating and issued a $2.50 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, June 30th. Stifel Nicolaus cut Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 13th. Royal Bank Of Canada cut Marinus Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $14.00 to $2.00 in a research note on Tuesday, June 14th. Finally, Zacks Investment Research raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Tuesday, July 5th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $7.80.

The stock has a 50-day moving average of $2.58 and a 200-day moving average of $4.65. The firm’s market capitalization is $37.65 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.04. Equities analysts expect that Marinus Pharmaceuticals Inc. will post ($1.47) EPS for the current year.

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.